The Searle Company Limited announced that it has entered into a license agreement with China’s Mabwell...
Publication Of Study Demonstrating Comparability Of AVT04 (Ustekinumab Biosimilar) And Stelara® In Moderate-To-Sever Chronic Plaque Psoriasis
A study comparing the efficacy, safety, tolerability, pharmacokinetics and immunogenicity between AVT04 (ustekinumab...
Sanofi receives marketing approval for Dupixent® (dupilumab)
Sanofi Healthcare India announced it has received marketing approval for Dupixent® (dupilumab) for the treatment of...
Samsung Bioepis releases second US Biosimilars Market Report
Samsung Bioepis has released its second US Biosimilar Market Report. The quarterly report has updated price details...
Samsung Biologics and Novartis announce US$310M manufacturing deal
Samsung Biologics announced in a regulatory filing with Korea Exchange that it has signed a ₩511B (US$390M) contract...
BeiGene and Novartis end option for collaboration and licence agreement to commercialise ociperlimab
BeiGene announced in an SEC filing that it and Novartis have entered into a mutual termination and release agreement,...
Cigna to prefer four adalimumab biosimilars at its formularies
Cigna Healthcare, a pharmacy manager, announced it will prefer adalimumab biosimilars Boehringer Ingelheim’s Cyltezo®,...
CuraTeQ Biologics enters into exclusive licence agreement with BioFactura, Inc to commercialise its biosimilar to Janssen’s Stelara® (ustekinumab)
Aurobindo Pharma announced that its wholly owned subsidiary, CuraTeQ Biologics, has entered into an exclusive license...
Biogen’s BYOOVIZ® (ranibizumab) to be reimbursed in Quebec
Biogen Canada announced that Quebec will reimburse patients receiving BYOOVIZ® (ranibizumab), biosimilar to...
Eisai/Biogen’s LEQEMBI® (lecanemab) receives traditional approval from FDA to treat AD
Biogen and Eisai announced that the FDA has approved the supplemental Biologics License Application (sBLA) for...
Biocon Biologics integrates Viatris’ biosimilars business in 70+ countries
Biocon Biologics announced it has completed the integration of Viatris’ biosimilars business in over 70 countries in...
Hisun Phase I tocilizumab study demonstrates bioequivalence with Genentech’s Actemra®
A Hisun phase I study has demonstrated pharmacokinetic similarity and bioequivalence between HS628, a proposed...
Phase III results for CuraTeQ Biologics’ BP02 (proposed trastuzumab biosimilar) show equivalence to Genentech’s Herceptin®
Aurobindo Pharma announced that CuraTeQ Biologics’ BP02 showed equivalence to Genentech’s Herceptin® in its phase III...
Samsung Biologics and Pfizer reach two manufacturing deals worth US$897M
Samsung Biologics announced it has reached two agreements with Pfizer to manufacture its biosimilar products for...
Organon and Samsung Bioepis announce launch of Hadlima®, biosimilar to AbbVie’s Humira® (adalimumab)
Organon and Samsung Bioepis announced that Hadlima®, biosimilar to AbbVie’s Humira® (adalimumab), is now available in...
Seven biosimilars to AbbVie’s Humira® (adalimumab) launch in US
Seven biosimilars to AbbVie’s Humira® (adalimumab): Coherus Biosciences’ Yusimry®, Organon and Samsung Bioepis'...